On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – RXi Pharmaceuticals Corp. (NASDAQ: RXII) Strengthens RXI-109 Intellectual Property with New Patent in Japan; Shares Rise

Company: RXi Pharmaceuticals Corp. (RXII)
Category: Stock Spotlights

RXi Pharmaceuticals (NASDAQ: RXII) shares are up more than 38% this morning after the company said it has been granted a patent by the Japan Patent Office for the composition of matter of sd-rxRNAs targeting connective tissue growth factor for the treatment or prevention of fibrotic disorders. Fibrotic disorders covered include, but are not limited to, skin fibrosis and proliferative retinopathy. This patent includes RXI-109, the company’s lead clinical candidate, which is currently being evaluated in phase 2 clinical trials. The patent will expire in 2031. “The granting of this patent in Japan further strengthens RXi’s intellectual property estate for future commercial and regional business development opportunities for RXI-109,” Chief Development Officer Pamela Pavco, Ph.D., stated in the news release.

To view the full press release, visit: http://nnw.fm/SXej0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to “silence” or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. The company’s current programs include dermatology, ophthalmology and cell-based immunotherapy. RXi’s extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and it actively pursues research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. Additional information may be found on the company’s website, www.rxipharma.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact us: 212.418.1217